Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG).

Full DD Report for AMAG

You must become a subscriber to view this report.


Recent News from (NASDAQ: AMAG)

AMAG Pharmaceuticals Pays Off $475 Million of Senior Secured Notes
WALTHAM, Mass., Sept. 06, 2018 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that it has redeemed $475 million of its outstanding 7.875% senior notes, using the proceeds from the sale of Cord Blood Registry®, which closed on August 6, 2018. ȁ...
Source: GlobeNewswire
Date: September, 06 2018 08:00
AMAG Pharmaceuticals: A Well-Positioned Player In The Pharmaceutical Space
Editor's note: Seeking Alpha is proud to welcome Tien Duy Vo as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more » Due to nega...
Source: SeekingAlpha
Date: August, 27 2018 08:33
Factors of Influence in 2018, Key Indicators and Opportunity within AMAG Pharmaceuticals, Pier 1 Imports, Gogo, IDT, Axalta Coating, and Sprouts Farmers Market - New Research Emphasizes Economic Growth
NEW YORK, Aug. 23, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG), Pier 1 Imports, Inc. (NYSE:PIR)...
Source: GlobeNewswire
Date: August, 23 2018 07:40
Antares Pharma: Proven Business Model Set To Move Much Higher
Following a big move of Antares Pharma ( ATRS ) shares from about $2.00 at the beginning of 2018 to near $3.40 currently (70% gain) some investors may question the potential for further upside in the shares near term. However, near-term catalysts bode well for a continued rally through at leas...
Source: SeekingAlpha
Date: August, 20 2018 07:49
California Cryobank And Cord Blood Registry Combine To Create A Leading Life Sciences Platform
LOS ANGELES , Aug. 6, 2018 /PRNewswire/ --  California Cryobank , the world's leading donor sperm and donor egg bank, announced today that it has been acquired by GI Partners, a private equity investment firm, from leading healthcare investors Longitude Capital and NovaQuest Capital....
Source: PR Newswire
Date: August, 06 2018 16:45
AMAG Pharmaceuticals Completes Divestiture of Cord Blood Registry®
WALTHAM, Mass., Aug. 06, 2018 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced it has closed the previously announced divestiture of Cord Blood Registry (CBR®) to GI Partners, a private equity investment firm, for $530 million in an all cash sale. T...
Source: GlobeNewswire
Date: August, 06 2018 16:30
AMAG Pharmaceuticals Appoints Brian Robinson, M.D. as Senior Vice President of Medical Affairs
WALTHAM, Mass., Aug. 06, 2018 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced the appointment of Brian Robinson, M.D. as senior vice president, medical affairs, reporting into Julie Krop, M.D., chief medical officer and executive vice president, development. In ...
Source: GlobeNewswire
Date: August, 06 2018 07:30
AMAG Pharmaceuticals, Inc. (AMAG) CEO Bill Heiden on Q2 2018 Results - Earnings Call Transcript
AMAG Pharmaceuticals, Inc. (AMAG) Q2 2018 Results Earnings Conference Call August 02, 2018 08:00 AM ET Executives Linda Lennox - VP, IR Bill Heiden - President and CEO Nik Grund - Chief Commercial Officer Ted Myles - CFO Analysts Jessica Fye - JP Morgan Kyung Yang - Jef...
Source: SeekingAlpha
Date: August, 04 2018 11:08
AMAG Pharmaceuticals, Inc. 2018 Q2 - Results - Earnings Call Slides
The following slide deck was published by AMAG Pharmaceuticals, Inc. in conjunction with their 2018 Q2 earnings Read more ...
Source: SeekingAlpha
Date: August, 02 2018 14:31
AMAG Pharmaceuticals Q2 revenues up 12%
AMAG Pharmaceuticals ( AMAG +9.2% ) Q2 results : Revenues: $146.3M (+12.2%); Makena: $105.2M (+2.4%); Feraheme/MuGard: $37.8M (+36.5%); Intrarosa: $3.2M. More news on: AMAG Pharmaceuticals, Inc., Healthcare stocks news, Earnings news and commentary, Read more ...
Source: SeekingAlpha
Date: August, 02 2018 11:02

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-0823.6523.7523.9523.00459,629
2018-05-1723.9024.6524.8523.90598,719
2017-06-2016.7016.8517.3516.70752,740
2017-06-1916.4516.6517.2016.25903,417
2017-06-1616.0016.4016.5516.001,327,427

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1478,495156,03850.3051Short
2018-12-13136,473272,27250.1238Short
2018-12-12128,816190,31467.6860Short
2018-12-1149,66477,91663.7404Short
2018-12-10113,068159,20871.0190Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on AMAG.


About AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG)

Logo for AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG)

Not available

 

Contact Information

 

 

Current Management

  • Brian J. G. Pereira / President, CEO

Current Share Structure

  • Market Cap: $782,341,012 - 05/14/2018
  • Issue and Outstanding: 34,088,933 - 02/27/2018

 


Recent Filings from (NASDAQ: AMAG)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 04 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 03 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 25 2018
Statement of beneficial ownership of common stock by certain persons
Filing Type: SC 13GFiling Source: edgar
Filing Date: April, 05 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 23 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 01 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 27 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 15 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 14 2018
Statement of beneficial ownership of common stock by certain persons
Filing Type: SC 13GFiling Source: edgar
Filing Date: February, 14 2018

 

 


Daily Technical Chart for (NASDAQ: AMAG)

Daily Technical Chart for (NASDAQ: AMAG)


Stay tuned for daily updates and more on (NASDAQ: AMAG)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: AMAG)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in AMAG is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of AMAG and does not buy, sell, or trade any shares of AMAG. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/